Related Experiment Videos
SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma
Bin Xu1, Min-Hua Ye1, Shi-Gang Lv1
1Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Abstract:
SNORD47 is a member of the C/D box small nucleolar RNAs, which have been implicated in cancer development. We intended to investigate the therapeutic potential of SNORD47 in glioma. We found that the expression of SNORD47 was downregulated in glioma tissues samples and inversely associated with advanced tumor stage (WHO grade IV). Kaplan-Meier survival analysis revealed that glioma patients with high SNORD47 expression had longer overall survival than those with low SNORD47 expression. SNORD47 suppressed the proliferation of glioma cells and induced G2 phase arrest. In addition, upregulation of SNORD47 suppressed invasion and epithelial-mesenchymal transition in glioma cells, and combination treatment with lenti-SNORD47 could augment the anti-tumor effect of temozolomide. These results showed that SNORD47 acted as a tumor suppressor in glioma, and provided the potential anti-tumor function in glioma treatment.
Insights
Small nucleolar RNA SNORD47 acts as a tumor suppressor in glioma. Lower SNORD47 expression correlates with advanced stages and poorer survival, suggesting its therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- C/D box small nucleolar RNAs (snoRNAs) are implicated in cancer development.
- The role of SNORD47 in glioma, a primary brain tumor, remains largely unexplored.
Purpose of the Study:
- To investigate the expression, prognostic value, and therapeutic potential of SNORD47 in glioma.
- To elucidate the functional role of SNORD47 in glioma cell proliferation, invasion, and epithelial-mesenchymal transition (EMT).
Main Methods:
- Analysis of SNORD47 expression in glioma tissues.
- Kaplan-Meier survival analysis.
- In vitro experiments assessing SNORD47's effects on glioma cell proliferation, cell cycle, invasion, and EMT.
- Combination therapy studies with temozolomide.
Main Results:
- SNORD47 expression was downregulated in glioma tissues and inversely correlated with advanced tumor stage (WHO grade IV).
- High SNORD47 expression was associated with longer overall survival in glioma patients.
- Overexpression of SNORD47 suppressed glioma cell proliferation, induced G2 phase arrest, and inhibited invasion and EMT.
- Upregulation of SNORD47 potentiated the anti-tumor effect of temozolomide.
Conclusions:
- SNORD47 functions as a tumor suppressor in glioma.
- SNORD47 holds potential as a therapeutic target for glioma treatment, possibly in combination with standard chemotherapy.